LONDON – It took Astrazeneca plc just a little over three hours on Friday morning to reject an improved £50 (US$84.32) per share offer from Pfizer Inc., valuing the UK company at about £64 billion (US$107.94 billion), saying the terms are inadequate, substantially undervaluing Astrazeneca and are not a basis on which to engage.